Troponin I & Troponin T

Reference ranges

Severity and critical values

Conversion: 1 ng/mL = 1 µg/L = 1,000 ng/L

High (above the 99th percentile URL)

Low (below the URL)

A value below the URL does not rule out MI when it is drawn early after symptom onset. For serial testing, see Interpretation & Bedside Approach.

Step-by-step approach

1. Is it real? Confirm the draw time, tube, and absence of hemolysis, and know whether the assay is high-sensitivity (ng/L) or conventional (ng/mL).
2. How sick is the patient? Check rhythm, blood pressure, oxygenation and the 12-lead ECG. Decide whether ACS is possible.
3. Acute or chronic? Compare with any prior value and repeat per the algorithm. A trend beats a single value.
4. Look for ischemia. Symptoms, new ischemic ECG changes, new Q waves, new regional wall motion loss on imaging, or thrombus on angiography.
5. Name the mechanism. Type 1 MI, Type 2 MI, or non-ischemic myocardial injury. Each has a different treatment direction.
6. Escalate or dispose. ECG-positive or high-risk patients go to the ACS pathway. Low-risk patients with serial negative troponin may follow an early-discharge pathway.

Fourth Universal Definition of MI (2018): acute MI

Acute MI needs a rise, a fall or both in cardiac troponin, with at least one value above the 99th percentile URL. Add at least one of these:

• Symptoms of acute myocardial ischemia
• New ischemic ECG changes (ST changes, new LBBB, or T-wave inversion)
• Development of pathologic Q waves
• Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
• Coronary thrombus identified by angiography or autopsy

Same troponin pattern, different mechanism. Type 2 MI comes from a mismatch between oxygen supply and demand, not from coronary thrombosis.

Serial high-sensitivity algorithms

• ESC 2023: The 0 h/1 h algorithm is the best choice. The 0 h/2 h algorithm comes second. Use 0 h/3 h only where faster protocols are not available.
• Sex-specific URLs: The Fourth UDMI endorses sex-specific 99th percentiles for hs assays, and some US hs assays use them. ESC 2023 sticks with uniform cut-offs for its algorithms. Use the thresholds your lab reports.
• Cut-offs are assay-specific: Rule-out thresholds were set for at least 99% sensitivity and negative predictive value. Rule-in thresholds were set for at least 70% positive predictive value. Use the validated cut-offs for your assay.
• Deltas: The early absolute change at 1 or 2 hours stands in for the change over 3 to 6 hours.
• United States: The 2021 AHA/ACC chest pain guideline backs accelerated hs-cTn pathways (0/1 h or 0/2 h). The 2025 ACC/AHA/ACEP/NAEMSP/SCAI ACS guideline governs ACS management. Follow your ED's validated high-sensitivity pathway.

Pattern and what it suggests

Risk stratification and disposition

The HEART pathway pairs the HEART score (History, ECG, Age, Risk factors, Troponin) with serial troponin. In a single-center randomized trial of 282 emergency patients, early discharge rose from 18.4% to 39.7%. None of the patients discharged early had a major adverse cardiac event within 30 days. The original 2015 trial used conventional troponin at 0 and 3 hours. hs-cTn versions of HEART use your local validated 0/1 h or 0/2 h pathway. Generalize with care. Local validation matters.

Medications

• Nitroglycerin: for ischemic chest pain when blood pressure allows; see the nitroglycerin page. Avoid with hypotension (SBP below 90 mmHg), suspected right ventricular infarct (get a right-sided ECG for inferior STEMI), recent PDE-5 inhibitor use (sildenafil or vardenafil within 24 h, tadalafil within 48 h), or marked bradycardia or tachycardia.
• Beta-blockers: when not contraindicated, per protocol. Avoid in acute heart failure, low-output state or shock, bradycardia, and AV block. See the metoprolol page.
• Heparin and enoxaparin: anticoagulation in ACS per protocol; see the heparin and enoxaparin pages.
• Clopidogrel: P2Y12 inhibitor in ACS per protocol; see the clopidogrel page.

Doses depend on the protocol, so this page does not repeat them. The E3 medication pages carry the reference doses.

Type 2 MI: treat the trigger

Fix the driver first. Transfuse for significant anemia when indicated, correct hypoxemia, control rate or rhythm, and treat hypotension and sepsis. Coronary angiography decisions rest on ischemic features, not on the troponin value alone.

Definitive care and disposition

• Suspected ACS: Admit or transfer. Serial troponin, risk scoring and the invasive decision all follow the current ACS guideline.
• Normal serial high-sensitivity values with a low-risk pathway: Early discharge can be appropriate, but only under the local pathway, with outpatient follow-up.
• Non-ischemic injury: Treat the cause (heart failure, PE, sepsis, renal failure). Then reassess the trend.

Doses vary by protocol. Follow local protocols and medical direction and institutional policy.

Point-of-care testing

Most high-sensitivity troponin results come from the hospital lab. Some cartridge devices report troponin at the bedside. Before you apply any cut-off, confirm the assay name and reporting units. Don't run a high-sensitivity algorithm on a conventional result. A field troponin does not change the prehospital ECG and symptom decisions.

Before and during interfacility transport

• Record timestamps: symptom onset, 12-lead ECG time, and the time of each blood draw. Those times decide whether an early value can be interpreted at all.
• Treatments that change the picture en route: rhythm and blood pressure management, oxygenation, and any antithrombotic given. Document each time and dose.
• Serial draws: Send the receiving team the first draw time. Then the second draw falls at the protocol interval (1 h or 2 h for high-sensitivity pathways).
• Redirect: An ischemic ECG or STEMI heads to the PCI-capable destination. Don't wait for troponin. A normal troponin does not cancel transport.

Collection and handling

Medications, supplements and assay interference

Physiologic and biologic

Assay and device

Common misinterpretations

• Elevated troponin means MI.
• A chronically high value in CKD or heart failure means an acute event.
• A normal early troponin rules out MI.
• One high-sensitivity value can be read on its own, without the delta or the ECG.

What it measures

Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are cardiac-specific isoforms of the thin-filament regulatory complex. This page covers troponin in adults and children. CK-MB and myoglobin each have their own pages. Assays come in two kinds: high-sensitivity, reported in ng/L, or conventional, reported in ng/mL (legacy).

Physiology & regulation

• The troponin complex (C, I, T) sits on the thin filament, alongside tropomyosin.
• Calcium binds troponin C. That shifts tropomyosin and lets actin and myosin cross-bridge.
• cTnI and cTnT are not the skeletal muscle isoforms. That is why they are largely cardiac-specific. hs-cTnT can still rise in chronic skeletal muscle disease.
• Troponin leaks out when the myocyte membrane is damaged. Low-level leak from injured but viable cells is part of what high-sensitivity assays detect.
• Clearance is slow. Values stay up for days to weeks.

How it is measured

Serum or plasma, per the assay insert. Write the draw time on every sample. Hospital analyzers run high-sensitivity assays. Cartridge analyzers may run conventional ones. Turnaround depends on the lab.

Why it matters

Troponin is the reference marker for myocardial injury. ACS decisions, risk stratification and early discharge all run on it. Plenty of non-ACS critical illnesses raise it too. Read it through the trend and the clinical picture.